The Claim
Higher polygenic resilience scores for Alzheimer's disease are associated with a delay in the estimated age of amyloid-β onset by approximately 0.91 years per standard deviation increase in score, independent of APOE ε4 status, but do not predict whether an individual will accumulate amyloid-β above the pathological threshold.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with higher polygenic resilience scores for Alzheimer's disease experience amyloid-β accumulation later in life by about 0.91 years for each standard deviation increase in score, regardless of APOE ε4 status, but these scores cannot determine whether amyloid-β will reach pathological levels.
See the scientific wording
Higher polygenic resilience scores for Alzheimer's disease are associated with a delay in the estimated age of amyloid-β onset by approximately 0.91 years per standard deviation increase in score, independent of APOE ε4 status, but do not predict whether an individual will accumulate amyloid-β above the pathological threshold.
The body clears amyloid-β protein faster and prevents it from clumping together, which pushes back when harmful levels build up in the brain, but doesn't stop the protein from forming altogether.
What the research says
1 studyPeople with certain genetic traits that make them more resistant to Alzheimer’s tend to develop brain plaques about 9 months later than others, but those same genes don’t stop the plaques from forming at all.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.